Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
Updated data for Lilly's Inluriyo reinforce efficacy results as monotherapy and in combination with Verzenio® in ER+, HER2- advanced breast cancer
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
Lilly's Jaypirca significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Lilly's Jaypirca met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica
U.S. FDA approves expanded indication for Lilly's Jaypirca , the first and only non-covalent BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Lilly to present data from two positive Phase 3 studies of Jaypirca in chronic lymphocytic leukemia at the 2025 American Society of Hematology Annual Meeting
